Clinical Focus

  • Cancer > Thoracic Oncology
  • Interventional Pulmonology
  • Pleural Diseases
  • Solitary Lung nodule
  • Pulmonary Disease

Academic Appointments

Professional Education

  • Fellowship:Tulane University Internal Medicine Residency (2005) LA
  • Fellowship:Beth Israel Deaconess Medical Center Harvard Medical School (2006) MA
  • Board Certification: Critical Care Medicine, American Board of Internal Medicine (2005)
  • Fellowship:Stanford University Medical Center (2005) CA
  • Board Certification: Pulmonary Disease, American Board of Internal Medicine (2004)
  • Board Certification: Internal Medicine, American Board of Internal Medicine (2002)
  • Residency:Kaiser Permanente at Santa Clara (2002) CA
  • Internship:Kaiser Permanente at Santa Clara (2000) CA
  • Medical Education:New York Medical College (1999) NY


All Publications

  • Interventional Pulmonologist Perspective: Treatment of Malignant Pleural Effusion CURRENT TREATMENT OPTIONS IN ONCOLOGY Sweatt, A. J., Sung, A. 2014; 15 (4): 625-643
  • Simvastatin enhances bone morphogenetic protein receptor type II expression BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS Hu, H., Sung, A., Zhao, G. H., Shi, L. F., Qiu, D. M., Nishmura, T., Kao, P. N. 2006; 339 (1): 59-64


    Statins confer therapeutic benefits in systemic and pulmonary vascular diseases. Bone morphogenetic protein (BMP) receptors serve essential signaling functions in cardiovascular development and skeletal morphogenesis. Mutations in BMP receptor type II (BMPR2) are associated with human familial and idiopathic pulmonary arterial hypertension, and pathologic neointimal proliferation of vascular endothelial and smooth muscle cells within small pulmonary arteries. In severe experimental pulmonary hypertension, simvastatin reversed disease and conferred a 100% survival advantage. Here, modulation of BMPR2 gene expression by simvastatin is characterized in human embryonic kidney (HEK) 293T, pulmonary artery smooth muscle, and lung microvascular endothelial cells (HLMVECs). A 1.4kb BMPR2 promoter containing Egr-1 binding sites confers reporter gene activation in 293T cells which is partially inhibited by simvastatin. Simvastatin enhances steady-state BMPR2 mRNA and protein expression in HLMVEC, through posttranscriptional mRNA stabilization. Simvastatin induction of BMPR2 expression may improve BMP-BMPR2 signaling thereby enhancing endothelial differentiation and function.

    View details for DOI 10.1016/j.bbrc.2005.10.187

    View details for Web of Science ID 000233944500010

    View details for PubMedID 16297860